While we hope you find CMB Clinical Trials' social media information interesting, it is not intended to diagnose a health problem, disease, or condition or for selecting a specific course or method of treatment. It is also not meant for discussing other companies’ medicines or report medical conditions or side effects associated with investigational or marketed products.
CMB Clinical Trials information and content are provided for general, informational, and educational purposes only. And it must not be used to substitute professional advice, diagnosis or treatment provided by a physician or other qualified and licensed healthcare advisor or medical professional, or replace person to person examination and consultation.
If you participate in blogs, wikis, social networking websites, podcasts, forums, message, boards, or comments on web-articles via Twitter, Facebook, LinkedIn, etc., and share content, or import a blog or other content, you should be aware that any information you choose to disclose can be read, collected and used in forums, developers and other third parties. CMB Clinical Trials is not responsible for the information you choose to submit in these forums. Some content may be public and searchable on the internet, and other third parties may have copied and used the information you have shared.
It is also essential for you to note that when you enter data on social media sites (e.g., Facebook and Twitter) CMB Clinical Trials has no control over the security of it or the location of those servers where the data you entered sits.
Social Media Channels:
CMB Clinical Trials (Including Improving Treatments) currently has active Facebook, Twitter, and LinkedIn social media channels and an interactive website. We endeavor to answer questions or reply to comments posted whenever possible during office hours. We always try to answer comments within two working days. We can moderate or remove comments on CMB Clinical Trials' social media channels.
When we post, we are very keen to have users’ feedback and engagement. However, we cannot promise to answer every question that is asked or address every issue raised. If we receive several questions or comments on a similar topic, they may be replied to collectively rather than on an individual basis.
When CMB Clinical Trials posts detailed information, we typically provide links to copies of the relevant material on our websites. It is to assure readers that the material is genuine and comes from the CMB Clinical Trials.
CMB Clinical Trials endeavor to post and update social media regularly. Messages and information posted on social media websites can remain for months and years to come, which means each needs to be responsible for ensuring their communications are accurate, precise, fair, and not misleading.
Use of CMB Clinical Trials and Improving treatments Social Media Channels by Members of the Public:
This section outlines the standards for members of the public to observe when interacting with or about CMB Clinical Trials and Improving treatments via social media channels and the circumstances in which CMB Clinical Trials shall monitor your use and the action it may take in respect of breaches of this Notice.
Republish material from website/s (including republication on another website);
Sell, rent or sub-license material from the CMB Clinical Trials and Improving Treatments websites;
Show any material from the website in public;
Copy, duplicate, reproduce or otherwise exploit any material on our website for a commercial purpose;
Edit or otherwise modify any material on our website or produced by CMB Clinical Trials; or
Redistribute material from this website (except for contents specifically and expressly made available for redistribution).
Any material you submit to our websites or social media channels for whatever purpose, you do so granting CMB Clinical Trials worldwide, irrevocable, non-exclusive, royalty-free license to use, reproduce, adapt, translate, publish, and distribute the user content in any media, existing or future. You also grant us permission to get these rights sub-licensed.